These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29427652)

  • 1. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regulatory perspective on the evaluation of hallucinogen drugs for human use.
    Calderon SN; Hunt J; Klein M
    Neuropharmacology; 2018 Nov; 142():135-142. PubMed ID: 29180224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.
    Henningfield JE; Ashworth J; Heal DJ; Smith SL
    J Psychopharmacol; 2023 Jan; 37(1):33-44. PubMed ID: 36588452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.
    Heal DJ; Gosden J; Smith SL; Atterwill CK
    Neuropharmacology; 2023 Mar; 225():109375. PubMed ID: 36529260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies with psychedelic drugs in human volunteers.
    Sellers EM; Romach MK; Leiderman DB
    Neuropharmacology; 2018 Nov; 142():116-134. PubMed ID: 29162429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations in assessing the abuse potential of psychedelics during drug development.
    Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D
    Neuropharmacology; 2023 Feb; 224():109352. PubMed ID: 36455646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
    Johnson MW; Griffiths RR; Hendricks PS; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():143-166. PubMed ID: 29753748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatry & the psychedelic drugs. Past, present & future.
    Rucker JJH; Iliff J; Nutt DJ
    Neuropharmacology; 2018 Nov; 142():200-218. PubMed ID: 29284138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.
    Collins GT; Gerak LR; France CP
    Neuropharmacology; 2018 Nov; 142():63-71. PubMed ID: 29246856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches and issues in non-clinical evaluation of abuse and dependence.
    Moser P; Wolinsky T; Castagné V; Duxon M
    J Pharmacol Toxicol Methods; 2011; 63(2):160-7. PubMed ID: 20868759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of psychedelic use and opioid use disorders among illicit users in the United States.
    Pisano VD; Putnam NP; Kramer HM; Franciotti KJ; Halpern JH; Holden SC
    J Psychopharmacol; 2017 May; 31(5):606-613. PubMed ID: 28196428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why psychiatry needs psychedelics and psychedelics need psychiatry.
    Sessa B
    J Psychoactive Drugs; 2014; 46(1):57-62. PubMed ID: 24830186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States.
    Calderon SN; Klein M
    Neuropharmacology; 2014 Dec; 87():97-103. PubMed ID: 24727212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.
    Henningfield JE; Coe MA; Griffiths RR; Belouin SJ; Berger A; Coker AR; Comer SD; Heal DJ; Hendricks PS; Nichols CD; Sapienza F; Vocci FJ; Zia FZ
    Neuropharmacology; 2022 Nov; 218():109220. PubMed ID: 35987353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why MDMA therapy for alcohol use disorder? And why now?
    Sessa B
    Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.